Humabs BioMed recently announced its collaboration to further develop vaccines and immunotherapies for Agilvax.
Switzerland-based Humabs BioMed creates human monoclonal antibodies that have been developed from survivors of chronic and infectious illnesses. Previous studies have shown that these antibodies, an ideal resource for vaccines and immunotherapies, are effective in vitro and in vivo.
Agilvax will use the antibodies and their own affinity-selection technology to identify virus-like-particles from the antibodies. Pairing Agilvax’s affinity selection with Humabs’ antibodies will produce durable immune responses, similar to therapeutic monoclonal antibodies. This alliance could lead to the creation of vaccines and immunotherapies to treat diseases that previously had no treatments.
Agilvax has previously developed products into the pre-clinical proof of concept stage in as quickly as four to six months.
"Agilvax is committed to developing and increasing accessibility to targeted vaccines and immunotherapies,” Agilvax President and CEO Frederic Pericle said. “The utilization of Humabs' antibodies in our product development process greatly increases our ability to fulfill this mission. Using antibodies derived from patient survivors ensures the creation of vaccines and immunotherapies that produce strong and precise immune responses, and ultimately improves health outcomes and patient well-being."